Clinical Trial Update: CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical study of AmorePacific's TRPV1 antagonist for atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• AmorePacific TRPV1 antagonist (TRPV1 antagonist)

Snippet

Sponsor: Amorepacific Corporation | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED